Medtronic, IBM Watson launch Sugar.IQ diabetes assistant

#artificialintelligence

Two years after originally announcing it, Medtronic and IBM Watson have launched their joint platform the Sugar.IQ, a digital diabetes assistant. "It is designed for people who are currently using Guardian Connect; so made for people on multiple daily injections. It is a personal assistant a little bit like Alexa or Siri," Huzefa Neemuchwala, global head of digital health solutions and AI at Medtronic, said in a Facebook live informational session. "It is an intelligent assistant that keeps track of all of your information and has all of your information in one place. Then through Watson technology we use this information to power insights so we can better manage your diabetes so that you can spend more time in range."


Is "IBM Watson Health Imaging" the Future of Healthcare? - Nanalyze

#artificialintelligence

A track record of prior competency that is above and beyond the norm is what hiring managers look for when they recruit "top talent", as recruiters like to say. Usually "top talents" can command a premium in the market place because everybody wants to employ them. We can equate these "top talents" to top quality stocks. You often hear dividend investors talk about how top dividend growth stocks are "always too expensive". That comment usually refers to the yield for the stock being lower than average, which in the case of a quality stock just represents a greater anticipation of future growth.


IBM Watson Health Unveils Imaging AI Marketplace of FDA-Cleared Solutions -

#artificialintelligence

Today at RSNA, IBM Watson Health is announcing two new products, and showcasing a variety of partnerships and clients that are using our advanced technologies to improve the way radiologists deliver care. We are delighted to announce these collaborations at RSNA highlighting our advancements in medical imaging globally," said Anne Le Grand, General Manager, Imaging, Life Sciences, and Oncology, IBM Watson Health. "From helping clinicians to identify potential missed findings to seeing a summary view of patient records quickly, our innovative technologies are at the forefront of Watson Health's mission to help enable clinicians to more effectively respond to the world's most pressing health challenges." Clinical Review 3.0, a tool recently launched in the UK that analyzes medical imaging studies and their associated reports to identify potentially missed findings, facilitating higher quality and more comprehensive care for the patient. IBM Watson Health Imaging has recently engaged with Fortrus Ltd, to grow upon the reseller's strong relationship with the UK public sector, which includes a single supplier outcome-based Managed Services framework. The Imaging AI Marketplace is a single-source solution designed to help simplify the complex process of locating, purchasing, deploying and managing the vast array of AI imaging applications. The Imaging AI Marketplace is carefully curated and contains only FDA-cleared solutions alongside Watson Health developed AI solutions. Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional imaging, also recently signed an exclusive joint development agreement to develop an artificial intelligence software solution to support prostate cancer diagnostics and monitoring, utilizing MR imaging. This deal extends their earlier collaboration regarding liver cancer signed in January 2018. In addition, 4ways, a fast-growing private teleradiology network in the UK that enables UK-based radiologists to work remotely over a leading technology platform, has committed to underpin its ambitious growth strategy with IBM Watson Health's Merge PACS 8.0 platform, upgrading its current platform to support their business growth. Merge PACS is a workflow platform that is designed to help simplify physicians' reading activities and can empower IT leaders with advanced control of the flow of studies throughout the enterprise. "We're committed to constantly investing in and upgrading our IT provision to be able to offer our clients and partners the very best service.


First FDA-approved medical AI to spy eyes proves completely autonomous

#artificialintelligence

The first FDA-approved AI system for diagnosing eye diseases caused by diabetes is completely autonomous, and doesn't require a doctor to interpret the results. Several corporations including Google and DeepMind have been working on building algorithms for diabetic retinography, a leading cause of blindness amongst adults. The first biz to release a device approved by the US Food and Drug Administration (FDA) earlier this year in April, however, is less well-known. IDx LLC, an AI diagnostics company based in Iowa, developed the tool known as IDx-DR. The details about the system were published in a paper in Nature Digital Medicine on Tuesday.


An A.I. Pioneer Wants an FDA for Facial Recognition

#artificialintelligence

Erik Learned-Miller is one reason we talk about facial recognition at all. In 2007, years before the current A.I. boom made "deep learning" and "neural networks" common phrases in Silicon Valley, Learned-Miller and three colleagues at the University of Massachusetts Amherst released a dataset of faces titled Labelled Faces in the Wild. To you or me, Labelled Faces in the Wild just looks like folders of unremarkable images. You can download them and look for yourself. There's boxer Joe Gatti, gloves raised mid-fight.